Pemphigus: Current and Future Therapeutic StrategiesDario Didona, Michael Hertl, Roberto Maglie et al.|Frontiers in Immunology|2019Cited by 245
Targeted Therapies for Autoimmune Bullous Diseases: Current StatusKyle T. Amber, Michael Hertl, Roberto Maglie et al.|Drugs|2018Cited by 86
Thymoma-Associated Paraneoplastic Autoimmune Multiorgan Syndrome—From Pemphigus to Lichenoid DermatitisFarzan Solimani, Michael Hertl, Takashi Hashimoto et al.|Frontiers in Immunology|2019Cited by 44
Human Desmocollin 3‒Specific IgG Antibodies Are Pathogenic in a Humanized HLA Class II Transgenic Mouse Model of PemphigusChristoph Hudemann, Rüdiger Eming, Roberto Maglie et al.|Journal of Investigative Dermatology|2021Cited by 31
Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigusDario Didona, Michael Hertl, Christoph Hudemann et al.|British Journal of Dermatology|2025Cited by 5